Zelira Therapeutics’ Hope range of autism cannabinoid medicines are now available to Australian patients by prescription under the TGA’s Special Access Scheme and through authorised prescribers.
Hope is part of Zelira’s suite of medicinal cannabis formulations consisting of two pharmaceutical-grade proprietary formulations targeting Autism Spectrum Disorder (ASD).
Zelira Therapeutics managing director Dr Richard Hopkins (pictured) said: “Following the success of the Hope launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia.
“This represents another key milestone in our commitment to bring the benefits of Hope to patients in global markets.
“We believe Hope can help support the unmet needs of the ASD community in Australia and look forward to working with all stakeholders to ensure they can access the benefits that medicinal cannabis can provide.”
The Hope range will be distributed nationally via Health House Holdings.